Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18436589 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | February 2024 | February 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18525072 | COLON TARGETED DRUG DELIVERY | November 2023 | January 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18124943 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | March 2023 | December 2024 | Abandon | 20 | 3 | 0 | No | No |
| 17990332 | USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION | November 2022 | February 2025 | Abandon | 27 | 2 | 0 | No | No |
| 17996545 | COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS | October 2022 | March 2025 | Abandon | 29 | 2 | 0 | No | Yes |
| 17655672 | TREATMENT OF BREAST CANCER | March 2022 | February 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17695489 | COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS | March 2022 | February 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17695464 | COMPOSITIONS FOR THE TREATMENT OF VIRAL PULMONARY INFECTIONS | March 2022 | February 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17654203 | TRANSDERMAL FORMULATIONS | March 2022 | February 2025 | Abandon | 35 | 2 | 0 | No | No |
| 17650156 | SOLUBILIZED MELATONIN | February 2022 | February 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17600639 | PHARMACEUTICAL COMPOSITION COMPRISING ESOMEPRAZOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HAVING DOUBLE-RELEASE PROFILE | October 2021 | December 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17442224 | MULTIPLE EMULSION COMPRISING AN OIL CONTINUOUS NANOEMULSION AND A METHOD FOR USING THE SAME | September 2021 | April 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17472225 | LIPONUCLEOTIDE-BASED THERAPY FOR COPD | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17434504 | FLOWABLE CONCENTRATE COMPOSITION FOR AGRICULTRUAL SEEDS | August 2021 | April 2025 | Abandon | 44 | 2 | 1 | Yes | No |
| 17347583 | BIOCIDAL SURFACE | June 2021 | February 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17272086 | DICHALCOGENIDE TITANIUM OXIDE MATERIALS FOR DISINFECTION | February 2021 | October 2024 | Abandon | 44 | 4 | 1 | No | No |
| 17042128 | MOLECULAR SIEVE/FIBER COMPOSITE MATERIAL AND PREPARATION METHOD THEREOF | November 2020 | March 2025 | Abandon | 54 | 2 | 1 | No | No |
| 17006830 | Phenolic aerosol sprays comprising thymol | August 2020 | February 2022 | Abandon | 18 | 2 | 1 | Yes | No |
| 16945398 | PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | July 2020 | November 2024 | Abandon | 51 | 4 | 0 | Yes | No |
| 16945195 | Suppression of Cytokine Release and Cytokine Storm | July 2020 | February 2025 | Abandon | 54 | 5 | 1 | Yes | No |
| 16505474 | OPTIMIZING DRUG DELIVERY | July 2019 | January 2021 | Abandon | 18 | 4 | 0 | No | Yes |
| 16141508 | CHEWABLE DOSAGE FORMS CONTAINING SITAGLIPTIN AND METFORMIN | September 2018 | May 2021 | Abandon | 32 | 2 | 0 | No | No |
| 15977456 | SUSTAINED-RELEASE TOPICALLY ADMINISTERED AGENT | May 2018 | October 2020 | Abandon | 30 | 2 | 0 | No | No |
| 15770411 | A Medical Composition and a Medical Hydrogel for Use in the Prevention and/or Treatment of a Disease of the Facet Joints and/or for Use in the Replacement and/or Regeneration of Articular Facets | April 2018 | March 2021 | Abandon | 35 | 2 | 1 | No | No |
| 15742792 | ILEUM-TARGETING, MUCOADHESIVE THIOLATED HPMCP VACCINE PROTEIN DELIVERY AGENT | January 2018 | June 2021 | Abandon | 41 | 3 | 1 | No | No |
| 15561763 | DENTAL MEMBRANE | September 2017 | November 2021 | Abandon | 49 | 2 | 1 | No | Yes |
| 15701465 | ORAL-SURFACE ADMINISTERED PREPARATION FOR THE PREVENTION OF ILLNESSES ACQUIRED VIA THE ORAL CAVITY AND THE PHARYNX | September 2017 | September 2021 | Abandon | 48 | 6 | 1 | Yes | No |
| 15356096 | MUCOADHESIVE DEVICES FOR DELIVERY OF ACTIVE AGENTS | November 2016 | December 2017 | Abandon | 13 | 1 | 0 | No | No |
| 15336158 | LIPOSOME COMPOSITION AND METHOD FOR PRODUCING SAME | October 2016 | November 2017 | Abandon | 13 | 1 | 0 | No | No |
| 15210277 | METHODS FOR INHIBITING COMPLEMENT ACTIVATION AND USES THEREOF | July 2016 | January 2018 | Abandon | 18 | 1 | 1 | Yes | No |
| 15192704 | NOVEL FORMULATIONS OF VOLATILE ANESTHETICS AND METHODS OF USE FOR REDUCING INFLAMMATION | June 2016 | June 2021 | Abandon | 59 | 4 | 1 | No | No |
| 14926622 | STABLE LIPOSOMAL FORMULATIONS OF ALPHA 2 ADRENERGIC AGONISTS FOR OCULAR DELIVERY | October 2015 | September 2017 | Abandon | 23 | 1 | 0 | No | No |
| 14926482 | Method for Making Liposomes Containing an Active Pharmaceutical Ingredient | October 2015 | August 2017 | Abandon | 21 | 1 | 0 | No | No |
| 14496992 | METHODS FOR COATING BONE ALLOGRAFTS WITH PERIOSTEUM-MIMETIC TISSUE ENGINEERING SCAFFOLDS | September 2014 | October 2021 | Abandon | 60 | 9 | 1 | No | Yes |
| 14495474 | MANAGEMENT SYSTEM AND METHOD FOR A BIG DATA PROCESSING DEVICE | September 2014 | October 2018 | Allow | 48 | 3 | 0 | Yes | No |
| 14375578 | TREATMENT OF MICROBIAL INFECTIONS | July 2014 | September 2017 | Abandon | 37 | 4 | 0 | Yes | No |
| 14241155 | MOLECULE MIXTURE COMPRISING AN AMPHIPATHIC MOLECULE TYPE A, WHICH HAS A POSITIVE TOTAL CHARGE IN THE HYDROPHILIC RANGE, AND AN AMPHIPATHIC MOLECULE TYPE B AND A POLYPHENOL C, METHOD FOR PRODUCING SAID MOLECULE MIXTURE AND USE THEREOF | February 2014 | January 2017 | Allow | 35 | 5 | 0 | No | No |
| 13884652 | SUSTAINED RELEASE COMPOSITIONS | May 2013 | April 2025 | Abandon | 60 | 13 | 0 | No | Yes |
| 13452212 | USE OF THE COMBINATION OF TERIFLUNOMIDE AND GLATIRAMER ACETATE FOR TREATING MULTIPLE SCLEROSIS | April 2012 | November 2013 | Abandon | 19 | 2 | 0 | No | No |
| 13335464 | Dental Compositions for Improving Brushing Habits | December 2011 | October 2013 | Abandon | 21 | 1 | 0 | No | No |
| 13079267 | TRANSDERMAL ADMINISTRATION OF HYDROPHILIC DRUGS USING PERMEATION ENHANCER COMPOSITION | April 2011 | February 2013 | Abandon | 22 | 1 | 0 | No | No |
| 12735722 | PRESERVED PRODUCT; AND PRESERVATIVE COMPOSITION | September 2010 | January 2012 | Abandon | 17 | 1 | 1 | No | No |
| 12887921 | TOOTH COATING COMPOSITION | September 2010 | April 2012 | Abandon | 19 | 1 | 0 | No | No |
| 12920734 | CHEWING GUM CONTAINING EUCALYPTUS EXTRACT | September 2010 | February 2012 | Abandon | 18 | 2 | 0 | No | No |
| 12680399 | MATERIAL COMPOSITION FOR ORAL HYGIENE PRODUCT | July 2010 | February 2012 | Abandon | 23 | 1 | 1 | No | No |
| 12812064 | GEL FOR TEETH TISSUES REMINERALIZATION | July 2010 | March 2012 | Abandon | 20 | 1 | 0 | No | No |
| 12678780 | STABLE CHEWING GUM COMPOSITIONS COMPRISING MALTITOL AND PROVIDING RAPID RELEASE OF NICOTINE | June 2010 | January 2012 | Abandon | 22 | 1 | 0 | No | No |
| 12802955 | Drink container with a breath strip | June 2010 | October 2011 | Abandon | 16 | 1 | 1 | No | No |
| 12665648 | MOUTHWASH COMPOSITION COMPRISING XANTHAN GUM AND SODIUM FLUORIDE | June 2010 | March 2012 | Abandon | 27 | 2 | 0 | No | No |
| 12792278 | Tooth-Cleaning Formulation | June 2010 | February 2012 | Abandon | 21 | 1 | 1 | No | No |
| 12524702 | BIORESORBABLE METAL STENT WITH CONTROLLED RESORPTION | May 2010 | February 2013 | Abandon | 43 | 2 | 0 | No | No |
| 12755687 | Mucositis Prevention Supplement and Treatment | April 2010 | May 2012 | Abandon | 25 | 1 | 1 | No | No |
| 12678552 | ORLISTAT PHARMACEUTICAL FORMULATIONS | March 2010 | February 2013 | Abandon | 35 | 0 | 1 | No | No |
| 12376342 | MICROBUBBLES AS DRUG DELIVERY DEVICE | March 2010 | February 2012 | Abandon | 37 | 0 | 1 | No | No |
| 12714739 | CONTROLLED RELEASE OF DRUGS INTO/THROUGH THE SKIN | March 2010 | February 2013 | Abandon | 35 | 2 | 0 | No | No |
| 12714162 | Bionanocomposite Materials and Methods For Producing and Using the Same | February 2010 | February 2013 | Abandon | 35 | 1 | 1 | No | No |
| 12640046 | COLOR TEST COMPOSITION FOR DENTAL TREATMENT | December 2009 | February 2013 | Abandon | 38 | 1 | 0 | No | No |
| 12602189 | METHOD FOR MODULATING THE TASTE OF MATERIAL COMPOSITIONS CONTAINING AT LEAST ONE HIGH INTENSITY SWEETENER (HIS) | November 2009 | March 2012 | Abandon | 27 | 2 | 0 | No | No |
| 12588825 | Compositions, articles and methods for preventing or reducing tobacco-associated damage | October 2009 | January 2012 | Abandon | 26 | 1 | 1 | No | No |
| 12562486 | 1-tert-Butylcyclohexanecarboxamide and uses thereof as cooling compounds | September 2009 | February 2013 | Abandon | 41 | 2 | 0 | No | No |
| 11992292 | Imaging Agents | July 2009 | March 2012 | Abandon | 48 | 0 | 1 | No | No |
| 12523938 | ANTIMICROBIAL COMPOSITION | July 2009 | April 2012 | Abandon | 33 | 0 | 1 | No | No |
| 12494356 | PHARMACEUTICAL COMPOSITION COMPRISING FLUOCINONIDE | June 2009 | January 2012 | Abandon | 30 | 1 | 0 | No | No |
| 12375751 | ORAL COMPOSITIONS EFFECTIVE FOR THE TREATMENT OF ORAL CAVITY MALODOR ASSOCIATED WITH THE CONSUMPTION OF ODOR-CAUSING COMPOUNDS | June 2009 | March 2012 | Abandon | 37 | 0 | 1 | No | No |
| 12517022 | PHARMACEUTICAL COMPOSITION OF MEMANTINE | May 2009 | January 2012 | Abandon | 31 | 0 | 1 | No | No |
| 12300662 | TABLET FORMULATION | April 2009 | January 2012 | Abandon | 38 | 1 | 1 | No | No |
| 11577902 | OXCARBAZEPINE DOSAGE FORMS | April 2009 | January 2012 | Abandon | 57 | 1 | 0 | No | No |
| 12443725 | Bi-component oral treatment composition | March 2009 | January 2012 | Abandon | 33 | 0 | 1 | No | No |
| 12350427 | METHOD AND COMPOSITIONS FOR ADMINISTERING RESVERATROL AND PTEROSTILBENE | January 2009 | February 2013 | Abandon | 49 | 4 | 0 | No | Yes |
| 12347082 | DISINFECTANT COMPOSITIONS, METHODS AND SYSTEMS | December 2008 | March 2012 | Abandon | 38 | 1 | 0 | No | No |
| 12308242 | Type-2 Diabetes Combination Wafer | December 2008 | January 2012 | Abandon | 37 | 0 | 1 | No | No |
| 12313678 | Compositions for preventing and/or treating gingivitis | November 2008 | February 2012 | Abandon | 39 | 0 | 1 | No | No |
| 12269767 | TAKEOVER PROCESSES IN SECURITY NETWORK INTEGRATED WITH PREMISE SECURITY SYSTEM | November 2008 | November 2011 | Allow | 36 | 2 | 0 | No | No |
| 12291482 | Nutritional composition and method for increasing creatine uptake and retention in skeletal muscle, increasing muscle mass and strength, increasing exercise capacity and for aiding recovery following exercise | November 2008 | January 2012 | Abandon | 38 | 2 | 0 | No | No |
| 12297416 | DIETARY AND PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES AND THEIR DERIVATIVES AND THEIR USES | October 2008 | May 2010 | Abandon | 19 | 1 | 1 | No | No |
| 12287922 | Nail polish | October 2008 | January 2012 | Abandon | 39 | 1 | 0 | No | No |
| 12094605 | Oral cavity care curative and prophylactic composition | September 2008 | March 2012 | Abandon | 46 | 0 | 1 | No | No |
| 12193792 | COMPOSITION COMPRISING A SOYBEAN OIL DERIVATIVE AND/OR A SALT THEREOF | August 2008 | January 2012 | Abandon | 41 | 1 | 0 | No | No |
| 12217192 | Composition comprising polyphenol | July 2008 | April 2010 | Abandon | 22 | 1 | 1 | No | No |
| 12217275 | Composition comprising polyphenol | July 2008 | April 2010 | Abandon | 22 | 1 | 1 | No | No |
| 12217274 | Composition comprising polyphenol | July 2008 | April 2010 | Abandon | 25 | 1 | 1 | No | No |
| 12112468 | TOOTH POWDER CONTAINING ELVAN AS RADIATION SOURCE OF FAR INFRARED RAY | April 2008 | February 2012 | Abandon | 46 | 1 | 0 | No | No |
| 12071756 | Synthetic bone graft | February 2008 | February 2013 | Abandon | 60 | 2 | 1 | No | No |
| 11597647 | Oral and/or Topical Compositions Comprising Prebiotics and Sterols | February 2008 | May 2010 | Abandon | 42 | 1 | 0 | No | No |
| 11916274 | Mouthwash for the Prevention and Treatment of Halitosis | November 2007 | January 2012 | Abandon | 49 | 1 | 1 | No | No |
| 11946020 | Soft Gel Formulations | November 2007 | February 2013 | Abandon | 60 | 2 | 1 | No | No |
| 11915011 | Microcapsule Composition | November 2007 | July 2010 | Abandon | 32 | 2 | 0 | No | No |
| 11904420 | Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User | September 2007 | May 2010 | Abandon | 32 | 1 | 1 | No | No |
| 11705675 | Low flush niacin formulation | February 2007 | October 2010 | Abandon | 44 | 1 | 1 | No | No |
| 11516896 | METHODS FOR WHITENING TEETH | September 2006 | October 2008 | Allow | 26 | 6 | 1 | Yes | No |
| 10974004 | SPRING POWERED NEEDLE-FREE INJECTION SYSTEM | October 2004 | June 2008 | Allow | 44 | 5 | 0 | Yes | No |
| 10881761 | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions | June 2004 | February 2013 | Abandon | 60 | 6 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KRASS, FREDERICK F.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KRASS, FREDERICK F works in Art Unit 1612 and has examined 91 patent applications in our dataset. With an allowance rate of 5.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner KRASS, FREDERICK F's allowance rate of 5.5% places them in the 0% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KRASS, FREDERICK F receive 1.92 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by KRASS, FREDERICK F is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +27.5% benefit to allowance rate for applications examined by KRASS, FREDERICK F. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 5.7% of applications are subsequently allowed. This success rate is in the 1% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 0.0% of appeals filed. This is in the 0% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 75.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.